Drug data last refreshed 2d ago · AI intelligence enriched 5d ago
VENTOLIN HFA is a metered-dose inhaler (MDI) containing albuterol sulfate, a beta-2 agonist bronchodilator used to treat acute bronchospasm and prevent exercise-induced asthma. It works by stimulating beta-2 adrenergic receptors in airway smooth muscle, causing rapid bronchodilation. This is a foundational rescue therapy in asthma and COPD management.
As LOE approaches, the brand team is likely in defense/maintenance mode with focus on brand loyalty programs and cost management rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Worked on VENTOLIN HFA at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$193M Medicare spend — this is a commercially significant brand
Roles linked to VENTOLIN HFA in 2024 are minimal (0 identified), reflecting the mature, LOE-approaching lifecycle. Positions on this product typically focus on defending market share, managing generics/biosimilar competition, and optimizing reimbursement rather than launching or scaling new indications.